ACT Capital Partners L.P. acquired a new stake in shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the 3rd quarter, HoldingsChannel.com reports. The firm acquired 220,200 shares of the biotechnology company’s stock, valued at approximately $7,179,000. Viking Therapeutics makes up about 4.7% of ACT Capital Partners L.P.’s investment portfolio, making the stock its 8th biggest position.
Several other hedge funds have also recently modified their holdings of VKTX. Choreo LLC boosted its position in shares of Viking Therapeutics by 6.9% during the third quarter. Choreo LLC now owns 6,660 shares of the biotechnology company’s stock worth $217,000 after acquiring an additional 429 shares during the last quarter. Assetmark Inc. grew its stake in Viking Therapeutics by 13.6% during the first quarter. Assetmark Inc. now owns 3,870 shares of the biotechnology company’s stock valued at $126,000 after acquiring an additional 462 shares in the last quarter. RFG Advisory LLC grew its stake in Viking Therapeutics by 0.3% during the second quarter. RFG Advisory LLC now owns 142,790 shares of the biotechnology company’s stock valued at $5,570,000 after acquiring an additional 463 shares in the last quarter. Russell Investments Group Ltd. increased its holdings in Viking Therapeutics by 1.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 45,075 shares of the biotechnology company’s stock valued at $1,469,000 after acquiring an additional 562 shares during the last quarter. Finally, NewEdge Advisors LLC increased its holdings in Viking Therapeutics by 3.6% in the 2nd quarter. NewEdge Advisors LLC now owns 16,533 shares of the biotechnology company’s stock valued at $645,000 after acquiring an additional 577 shares during the last quarter. Hedge funds and other institutional investors own 76.03% of the company’s stock.
Analyst Ratings Changes
Several analysts have commented on the stock. HC Wainwright reiterated a “buy” rating on shares of Viking Therapeutics in a research note on Tuesday, September 22nd. The Goldman Sachs Group restated a “neutral” rating and set a $34.00 price objective on shares of Viking Therapeutics in a research report on Thursday, October 29th. Barclays upgraded Viking Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 13th. UBS Group started coverage on Viking Therapeutics in a report on Wednesday, October 14th. They issued a “buy” rating and a $94.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Viking Therapeutics in a research report on Thursday, October 15th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $93.36.
Check Out Our Latest Stock Analysis on Viking Therapeutics
Viking Therapeutics Trading Up 5.9%
NASDAQ:VKTX traded up $1.64 during mid-day trading on Friday, hitting $29.22. 8,859,375 shares of the stock traded hands, compared to its average volume of 4,139,148. Viking Therapeutics, Inc. has a 52 week low of $23.82 and a 52 week high of $43.10. The company has a quick ratio of 7.27, a current ratio of 7.27 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $3.73 billion, a price-to-earnings ratio of -5.41 and a beta of 0.79. The firm’s 50 day moving average is $29.33 and its two-hundred day moving average is $32.16.
Viking Therapeutics (NASDAQ:VKTX – Get Free Report) last announced its quarterly earnings data on Wednesday, October 28th. The biotechnology company reported ($1.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.49). During the same quarter in the prior year, the company posted ($0.81) EPS. On average, equities research analysts predict that Viking Therapeutics, Inc. will post -5.26 earnings per share for the current year.
Viking Therapeutics Company Profile
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California. Founded in 2012, it develops medicines for metabolic and endocrine disorders and does not have commercially marketed products. The company’s pipeline includes VK2735, an investigational drug that targets the GLP-1 and GIP receptors and is being developed for obesity, and VK2809, a thyroid hormone receptor beta agonist being studied for metabolic and liver conditions. Viking is also developing VK0214 for X-linked adrenoleukodystrophy, a rare genetic disorder.
Featured Stories
- Five stocks we like better than Viking Therapeutics
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
- Is It Too Late to Buy the Dip? 3 Corners of the Market Still Offering Real Value
Want to see what other hedge funds are holding VKTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report).
Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
